Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlmirallCHIX:ALME 85 EV-to-OCF is 9.61 as of Aug. 07, 2026, which is 34% below its 10-year median of 14.58. GuruFocus rates CHIX:ALME with a GF Score™ of 85/100 and a GF Value™ of €14.69. The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Almirall ranks better than 53.13% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Almirall's Enterprise Value is €2,390 Mil.
Almirall's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €249 Mil. Therefore, Almirall's EV-to-OCF for today is 9.61.
The historical rank and industry rank for Almirall's EV-to-OCF or its related term are showing as below:
CHIX:ALMe'
s EV-to-OCF Range Over the Past 10 Years
Min: -184.4 Med: 14.58 Max: 277.68
Current: 9.71
During the past 13 years, the highest EV-to-OCF of Almirall was 277.68. The lowest was -184.40. And the median was 14.58.
CHIX:ALMe's EV-to-OCF is ranked better than 53.13% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.87
vs CHIX:ALMe: 9.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Almirall's share price for today is €12.71.
Almirall's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.329.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Almirall EV-to-OCF Related Terms
Almirall EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Almirall's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALME vs ZTS, UTHR, VTRS: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almirall EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Almirall's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Almirall's EV-to-OCF falls into.
Almirall's current Enterprise Value is €2,390 Mil.
Almirall's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €249 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall (CHIX:ALME) has a EV-to-OCF of 9.61 as of Aug. 07, 2026. This is 34% below median its historical median of 14.58. According to the industry distribution chart, Almirall ranks #472 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Almirall's EV-to-OCF too high?
Almirall's current EV-to-OCF of 9.61 is 34% below median its 10-year median of 14.58. The Drug Manufacturers industry median EV-to-OCF is 10.87. Almirall's value of 9.61 is 11.6% below this industry median. Based on the distribution chart, Almirall ranks #472 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Almirall has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Almirall's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #472 out of 1007 companies for EV-to-OCF. This puts Almirall in the upper half of its industry. The industry median EV-to-OCF is 10.87. Almirall's value of 9.61 is 11.6% below this benchmark. While the company's 10-year median is 14.58 vs. the industry median of 10.87, Almirall has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.87, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current EV-to-OCF of 9.61 is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current EV-to-OCF is 9.61, which is 34% below median its own 10-year median of 14.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Almirall (CHIX:ALME) has a current EV-to-OCF of 9.61. The stock's GF Value™ is €14.69, compared to a current price of €12.71 — trading 13.5% below its estimated fair value. The current EV-to-OCF is 9.61, which is 34% below median its 10-year median of 14.58 and 11.6% below the Drug Manufacturers industry median of 10.87. Almirall's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Almirall (CHIX:ALME), the current EV-to-OCF is 9.61 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Almirall (CHIX:ALME) Overvalued in 2026?
Based on GuruFocus' analysis, Almirall stock appears to be undervalued.
The current stock price of €12.71 is trading 13.5% below its estimated GF Value™ of €14.69.
Key valuation signals for CHIX:ALME:
EV-to-OCF: 9.61 (34% below median its 10-year median of 14.58)
GF Value™: €14.69 vs. price of €12.71 (13.5% below fair value)
Industry Position: 11.6% below the Drug Manufacturers median (#472 of 1007)
No single metric tells the full story. See the CHIX:ALME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
85GF Score
Get the complete analysis for CHIX:ALME
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALME has been successfully added to your 
